Nasal Nitric Oxide Levels in Eosinophilic Esophagitis (EoE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01929824 |
Recruitment Status :
Completed
First Posted : August 28, 2013
Last Update Posted : September 30, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Eosinophilic Esophagitis | Other: Oral Nitric Oxide testing |
Study Type : | Observational |
Actual Enrollment : | 50 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Pilot Study: Nasal Nitric Oxide Levels in Eosinophilic Esophagitis. |
Actual Study Start Date : | August 2013 |
Actual Primary Completion Date : | September 25, 2017 |
Actual Study Completion Date : | September 25, 2019 |

- Other: Oral Nitric Oxide testing
o Oral nitric oxide is measured by a breathing test where the participant will be seated in a chair and asked to breathe out into a small hand-held instrument for about 6 seconds.
- Number of patients with increase in Oral Nitric Oxide levels [ Time Frame: one year ]To determine if oral NO correlates to activity of disease in EoE

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion criteria:
- Subjects with dysphagia and active esophageal infiltration (esophageal eosinophilic count of >/= 15 eos/hpf)
- Subjects with or without a clinical diagnosis of asthma
Exclusion criteria:
- Subjects with chronic cough
- Severe CAD
- MI within the last 3 months
- Cystic fibrosis
- Tuberculosis
- Chronic obstructive pulmonary disease (COPD)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01929824
United States, Minnesota | |
Mayo Clinic in Rochester | |
Rochester, Minnesota, United States, 55905 |
Principal Investigator: | Vivek Iyer, MD | Mayo Clinic |
Responsible Party: | Vivek N Iyer, Principal Investigator, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT01929824 |
Other Study ID Numbers: |
13-001194 |
First Posted: | August 28, 2013 Key Record Dates |
Last Update Posted: | September 30, 2019 |
Last Verified: | September 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
dysphagia, trouble swallowing, chest pain |
Esophagitis Eosinophilic Esophagitis Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Gastroenteritis Eosinophilia Leukocyte Disorders Hematologic Diseases Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Nitric Oxide Bronchodilator Agents |
Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Endothelium-Dependent Relaxing Factors Vasodilator Agents Gasotransmitters Protective Agents |